P I Industries Ltd (PIIND) Q2 FY27 Earnings Call: Guides Flattish FY27, Gross Margin Seen At 49%

P I Industries Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

A Difficult Quarter in a Difficult Year

• Consolidated revenue of Rs.17,018 million, down 9% YoY — Q2 FY 2026-2027 gross margin at 49% and EBITDA margin at 14%; management characterised the quarter as a low point in the global crop protection cycle.
• Agchem exports fell 18% YoY — management attributed roughly 3-4% to lower volumes and 13-14% to price/cost declines; the decline was broad-based across the portfolio, not driven by a single molecule.
• Domestic agri grew 19% YoY — supported by differentiated high-value crop protection solutions and flagship brand leadership despite the weakest monsoon in over a decade, delayed sowing and flat kharif acreage.
• Net working capital reduced by 18 days — releasing Rs.298 crores of cash as at Q2 FY 2026-2027 quarter end; operating cash flow of Rs.9.1 billion vs Rs.2.3 billion YoY, ending the quarter with net cash of Rs.36 billion.
• Margin bridge for Q2 FY 2026-2027 — input costs higher by 5%, new business development investments at 6%, R&D at 2%, and energy costs up 3%; management framed the headwinds (El Nino, genericization) as cyclical rather than structural.
• India season risk — soil moisture and reservoir levels are below last year in several regions; management is planning for a cautious Rabi in FY 2026-2027, though firming commodity prices, if sustained, point to better farm economics next season.

Genericization, Off-Patent Realizations and Deliberate Price Calls

• Pricing decline of ~13-14% in Q2 FY 2026-2027 — Mayank Singhal confirmed the discounting spans the core portfolio across both domestic and global markets, not product-specific.
• Key export molecule has gone off-patent — realization pressure plus higher raw material costs; management declined to give a "straight answer" on whether realizations have normalised, noting prices swing with the market. Stabilisation of the post-genericization lead-lag is expected in a couple of years (~FY 2028-2029).
• Pricing pressure now extends to patented/innovation-based molecules — Singhal explained pressure applies "even on innovation basis" when farmer economics weaken, as growers deprioritise value-proposition products (observation as of the Q2 FY 2026-2027 call).
• Deliberate share-defence pricing — PI, with strategic global partners, took pricing calls to defend market share rather than pass through cost inflation; management sees a limit to how much price increase customers can absorb, as lost share is harder to rebuild.
• Input-cost pressure expected to persist for 2-3 quarters — i.e., Q3 FY 2026-2027 through up to Q1 FY 2027-2028, per the analyst's recap of management's remarks; the strategy is to optimise and maximise volumes through price optimisation.
• Generic molecule pricing — on the largest generic molecule, management said current levels are "the best we see for today," with further moves to be market- and opportunity-led.

Domestic Strength and the Biologicals Platform

• Domestic biologicals grew 45% YoY — now 18% of the domestic agri portfolio in Q2 FY 2026-2027, driven by new launches and focused go-to-market.
• Global biologicals revenue grew 250%+ YoY — with a 3x increase in distribution width across Brazil, Mexico, Spain and the US, supported by registrations and field activities.
• Pioxomeriprol (branded Pioxazone) launched — PI's first new chemical entity received registration in India and launched in November 2026 (Q3 FY 2026-2027) as an insecticide for rice, corn and Bengal gram; the first season will gauge farmer adaptability at scale.
• Scale-up plans for the new molecule by end of FY 2026-2027 — label expansion beyond the current three crops is ongoing; no revenue guidance was committed for FY 2027-2028 onward until first-season commercial feedback is assessed.
• Biologicals go-to-market via partnerships — leveraging PI's platform for developed economies (Brazil, Mexico, America) through long-standing partners rather than a standalone front-end; commercial model (PI brand vs partner brand) left open per "best techno-commercial opportunity." Regulatory filings hoped for in FY 2027-2028 to FY 2028-2029, with some products possibly reaching market over FY 2028-2029 to FY 2029-2030 (aspirational, per management).

Pharma CRDMO, Electronic Chemicals and the Innovator Play

• Pharma CDMO target reaffirmed at Rs.5,000-6,000 crore — with EBITDA breakeven over the next 2-3 years (as stated on this FY 2026-2027 call): "that's our target. We still continue to work on that." Management did not specifically address the pharma CDMO contract slippage flagged in Q1 FY 2026-2027.
• Pharma revenue grew 20% YoY in Q2 FY 2026-2027 — ~Rs.75 crores for the quarter; Hyderabad drug-discovery centre of excellence is up, new QC labs at Lodi commissioned, kilo labs to be completed by end of FY 2026-2027.
• Electronic chemicals: targeting a $100 million business in niche areas over the next 3-4 years — (≈FY 2029-2030 to FY 2030-2031), with a good ramp-up expected in FY 2027-2028; kilo labs at Udaipur operational by end of FY 2026-2027. Per the analyst, 75% of new inquiries come from non-agchem.
• New-molecule portfolio peak potential — responding to an analyst's suggested $300-400 million, Singhal said "it could be that in 3 to 5 years" but explicitly declined to commit ("I would not hold myself to that number").
• 12+ molecules commercialized over the last 3-5 years — contributing 17-18% of revenue as of Q2 FY 2026-2027 (16-18% of the CSM export business in H1 FY 2026-2027); management expects the share to increase over time, flagging market dynamics as a swing factor. Three new CSM molecules were commercialized in Q2 FY 2026-2027.
• Innovator play gestation — management called the global ag innovator play the "biggest bend around the curve": gestation is already 12 years, with another 5-6 years before it creates a differentiated position.

Gross Margin Targets Held; Startup Costs Quantified

• Near-term gross margin view of 49% — management had guided 52-53% for FY 2026-2027 (set against an exceptional FY 2025-2026 base), but for the next 2-3 quarters (Q3 FY 2026-2027 through Q1 FY 2027-2028) it now sees 49%; beyond that window it is "too early to call." (A separate reference on the call reiterated a 50-52% gross margin target for FY 2026-2027, with FY 2025-2026 an exception year.)
• 48-49% gross margin target held for now — materials for Q3 FY 2026-2027 onward already lined up; any positive swing from reversal of input-cost inflation would take a couple of quarters to flow through. Management did not confirm the ~5 percentage points of upside posited by Tejas Pradhan (Citigroup).
• Overheads at Rs.609 crores vs Rs.530 crores — a ~Rs.70 crores YoY increase in Q2 FY 2026-2027, driven primarily by new business development and energy costs (CFO Sanjay Agarwal).
• New business/molecule launch costs of ~Rs.36 crores in Q2 FY 2026-2027 — spanning development of new businesses, energy costs and R&D startup costs run about 2-3 years and are expected to flatten over the next 2-3 years (FY 2027-2028 through FY 2029-2030) before turning positive.
• Global biologics loss of ~$10+ million for full-year FY 2026-2027 — confirmed by CFO Sanjay Agarwal on a full-year basis; new business development costs (~6% YoY increase) primarily from biologics footprint expansion into the US, Brazil and Mexico.
• Plant healthcare inflection expected within the next 2-3 years (by FY 2029-2030) — defined as the business turning EBITDA positive with stable growth numbers.

Flattish FY27, Order Book Discipline and Capex Posture

• Flattish approach for FY 2026-2027 — management walked back the low-single-digit growth indicated at the previous call, citing external dynamics and industry trends; green shoots in volume pickups and partner demand are expected by end of FY 2026-2027, with continued CSM pressure over Q3-Q4 FY 2026-2027.
• Order book of $1.25 billion as of Q2 FY 2026-2027 — management clarified the figure is contract-value based and can swing during the contract (cost increases have added pieces; challenged markets have led to discounting), describing it as a guideline rather than a precise number.
• Contract assets at ~Rs.700 crores — up only ~Rs.30 crores over H1 FY 2026-2027; CFO Sanjay Agarwal said these represent committed purchase orders for patented innovator products and expects them to remain in the same range from H2 FY 2026-2027 onward, consistent with volumes being shipped out.
• Ag chem capex at "saturated maturity" — existing capacity investments will "take care of the next 2 to 3 years in the ag chem sector"; incremental capex will be directed toward new growth engines across platforms.
• Inorganic growth under evaluation, not committed — the company is "continually evaluating" opportunities across agri, pharma and specialty platforms, with Singhal flagging agri biologicals as "a great opportunity"; no transaction, size or timeline announced.
• Next wave of 2-3 molecules in advanced stages — some markets should show results over the next 3 to 4 years; management said it is too early to size the markets but described the opportunities as sizable.